Search

Sirolimus

[A242417] Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

Cyclothiazide

This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. … It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Ioxitalamic acid

Until the last review in 2015, this drug is still available in the market.[L1113] … [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.

Padeliporfin

[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.

Moxetumomab pasudotox

CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.

Olsalazine

[A257063] Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151] … [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon.

Edetate calcium disodium anhydrous

[L12774] It is on the World Health Organization Model List of Essential Medicines.[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774] … Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body.

Enalapril

and renal reabsorption of sodium ions in the kidneys. … It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension.

Ferrous gluconate

Dapagliflozin

[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April